Compare FSUN & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSUN | CGEM |
|---|---|---|
| Founded | 1892 | 2016 |
| Country | United States | United States |
| Employees | 1186 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 904.7M |
| IPO Year | N/A | 2020 |
| Metric | FSUN | CGEM |
|---|---|---|
| Price | $36.91 | $13.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $45.00 | $30.13 |
| AVG Volume (30 Days) | 136.8K | ★ 1.1M |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $79.34 | N/A |
| Revenue Next Year | $14.67 | $5.20 |
| P/E Ratio | $11.30 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $29.95 | $5.68 |
| 52 Week High | $42.34 | $16.74 |
| Indicator | FSUN | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 59.03 | 44.43 |
| Support Level | $34.32 | $11.92 |
| Resistance Level | $37.12 | $16.31 |
| Average True Range (ATR) | 0.83 | 1.25 |
| MACD | 0.26 | -0.27 |
| Stochastic Oscillator | 94.66 | 35.58 |
Firstsun Capital Bancorp is the financial holding company. It provides a full range of deposit, lending, treasury management, wealth management, and online banking products and services. The company operates in two segments; Banking operations and mortgage operations, the majority of which are generated by the banking operations segment. The Banking segment originates loans and provides deposits and fee based services to consumer, business, and mortgage lending customers. Products offered include a full range of commercial and consumer banking and financial services. The Mortgage Operations segment originates, sells, services, and manages market risk from changes in interest rates on one-to-four family residential mortgage loans.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.